Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity

Korean Journal of Family Medicine

Volumn 34, Issue 5, 2013, Pages 298-306

  Kim, Hyun Ok ^a   Lee, Jung Ah ^a   Suh, Hee Won ^a   Kim, Young Sik ^a   Kim, Bum Soo ^b   Ahn, Eun Sook ^c   Roh, Young Jun ^d   Jung, Seong Gil ^e   Kim, Jin Mok ^f   Kang, Moon Kuk ^g   Ahn, In Soon ^h   Park, Young Gyu ⁱ  

^a University of Ulsan College of Medicine   (South Korea)

^b Haemalgeun Clinic   (South Korea)

^c Sungmo Family Medical Clinic   (South Korea)

^d Purun Medical Clinic   (South Korea)

^e Sejong Clinic   (South Korea)

^f Paradise Clinic   (South Korea)

^g Chungdam White Clinic   (South Korea)

^h Yonsei Pediatric Clinic   (South Korea)

ⁱ Bundang Jesaeng Hospital   (South Korea)

Author keywords

Efficacy; Obesity; Phentermine; Safety

Indexed keywords

EID: 84886062745     PISSN: 20056443     EISSN: 20926715     Source Type: Journal    
DOI: 10.4082/kjfm.2013.34.5.298     Document Type: Article

References (17)

1. Bray GA. The metabolic syndrome and obesity. Totowa (NJ): Humana Press; 2007.
2. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302.
3. World Health Organization; International Association for the Study of Obesity; International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000.
4. Statistics Korea. Population projections for Korea [Internet]. Daejeon: Statistics Korea; c1996-2009 [cited 2009 Nov 11]. Available from: http://www.kosis.kr/eng/.
5. Kaplan LM. Pharmacological therapies for obesity. Gastroenterol Clin North Am 2005;34:91-104.
6. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010;6:255-69.
7. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674.
8. Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasic JR, Wong DF. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 2005;56:94-9.
9. Cannistra LB, Gaasch WH. Appetite-suppressing drugs and valvular heart disease. Cardiol Rev 1999;7:356-61.
10. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a metaanalysis of observational studies. Am Heart J 2002;144:1065-73.
11. Kim BS, Kim YS, Ahn ES, Roh YJ, Jung SG, Kim MJ, et al. Postmarketing surveillance study on the efficacy and safety of phendimetrazine in patients with obesity. Korean J Health Promot Dis Prev 2010;10:97-103.
12. Choi CJ, Kim KS, Kim SR, Kang JH, Park HS. Doubleblind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients. Korean J Obes 2005;14:155-62.
13. Park HS, Kim KS, Kim BT, Lee KW, Ahn CW, Choi WH. Double-blind, randomized, multi-center, comparative clinical trial of sibutramine mesilate with sibutramine hydrochloride for evaluating efficacy and safety in obese patients. Korean J Obes 2008;17:82-90.
14. Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47:614-25.
15. Kay JM. Dietary pulmonary hypertension. Thorax 1994;49 Suppl:S33-8.
16. Rostagno C, Caciolli S, Felici M, Gori F, Neri Serneri GG. Dilated cardiomyopathy associated with chronic consumption of phendimetrazine. Am Heart J 1996;131:407-9.
17. Kim YS, Sunwoo S, Lee HR, Lee KM, Park YW, Shin HC, et al. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002;11:593-600.